1. WHO consolidated guidelines on tuberculosis Module 4: Treatment – drug-susceptible tuberculosis treatment. Geneva: World Health Organization; 2022.
  2. WHO operational handbook on tuberculosis Module 4: Treatment – tuberculosis care and support. Geneva: World Health Organization; 2022.
  3. The End TB Strategy (WHO/HTM/TB/2015.19). Geneva: World Health Organization; 2015 (https://www.
  4. WHO consolidated guidelines on tuberculosis Module 3: Diagnosis – rapid diagnostics for tuberculosis detection. Geneva: World Health Organization; 2021 (
  5. Global tuberculosis report 2021. Geneva: World Health Organization; 2021 ( publications/i/item/9789240037021)
  6. Ismail NA, Mvusi L, Nanoo A, Dreyer A, Omar SV, Babatunde S et al. Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national cross-sectional survey. Lancet Infect Dis. 2018;18(7):779–87 ( tuberculosis_and_imputed_burden_in_South_Africa_a_national_and_sub-national_cross-sectional_survey).
  7. Kayomo MK, Mbula VN, Aloni M, André E, Rigouts L, Boutachkourt F et al. Targeted next-generation sequencing of sputum for diagnosis of drug-resistant TB: results of a national survey in Democratic Republic of the Congo. Sci Rep. 2020;10(1):10786 (
  8. Lim DR, Dean AS, Taguinod-Santiago MR, Borbe-Reyes A, Cabibbe AM, Zignol M et al. Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey. Eur Respir J. 2018;51(3):1702571 (
  9. Mesfin AB, Araia ZZ, Beyene HN, Mebrahtu AH, Suud NN, Berhane YM et al. First molecular-based anti-TB drug resistance survey in Eritrea. Int J Tuberc Lung Dis. 2021;25(1):43–51 (https://pubmed.ncbi.nlm.nih. gov/33384044/).
  10. Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis. 2016;16(10):1185–92 ( population-based-resistance-of-mycobacterium-tuber).
  11. Dean AS, Zignol M, Cabibbe AM, Falzon D, Glaziou P, Cirillo DM et al. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: a multicountry analysis of cross-sectional data. PLoS Med. 2020;17(1):e1003008 (
  12. Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med. 2009;6(9):e1000150 (
  13. Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, Murray MB. Treatment outcomes of isoniazidresistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis. 2011;53(4):369–72 (
  14. Gegia M, Cohen T, Kalandadze I, Vashakidze L, Furin J. Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007–2009. Int J Tuberc Lung Dis. 2012;16(6):812–6 (https://pubmed.ncbi.nlm.nih. gov/22507372/)
  15. 5 Namugenyi J, Musaazi J, Katamba A, Kalyango J, Sendaula E, Kambugu A et al. Baseline Xpert MTB/RIF ct values predict sputum conversion during the intensive phase of anti-TB treatment in HIV infected patients in Kampala, Uganda: a retrospective study. BMC Infect Dis. 2021;21(1):513 (https://bmcinfectdis.biomedcentral. com/articles/10.1186/s12879-021-06220-6).
  16. Step Up for TB 2020. Geneva: Stop TB Partnership; 2020 ( step-tb-2020).
  17. Cazabon D, Pande T, Kik S, Van Gemert W, Sohn H, Denkinger C et al. Market penetration of Xpert MTB/ RIF in high tuberculosis burden countries: a trend analysis from 2014 - 2016. Gates Open Res. 2018;2:35 (
  18. WHO operational handbook on tuberculosis Module 4: Treatment – drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020 (
  19. Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2nd ed. Geneva: World Health Organization; 2014 ( handle/10665/112360/9789241548748_eng.pdf)
  20. WHO consolidated guidelines on tuberculosis Module 5: Management of tuberculosis in children and adolescents. Geneva: World Health Organization; 2022 ( retrieve).
  21. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(10 Suppl 2):S231–79 (
  22. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drugresistant tuberculosis. Lancet Infect Dis. 2010;10(9):621–9 (
  23. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2016 (https://apps.
  24. Modongo C, Wang Q, Dima M, Matsiri O, Kgwaadira B, Rankgoane-Pono G et al. Clinical and virological outcomes of TB/HIV coinfected patients treated with dolutegravir-based HIV antiretroviral regimens: programmatic experience from Botswana. J Acquir Immune Defic Syndr. 2019;82(2):111–5 (https://www.
  25. Alffenaar J-WC, Akkerman OW, Bothamley G. Monitoring during and after treatment. In: Migliori G, Bothamley G, Duarte R & Rendon A (eds.), Tuberculosis (ERS Monograph). Sheffield: European Respiratory Society; 2018:308–25 (
  26. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR et al. Four-month moxifloxacinbased regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371(17):1577–87 (https://www.nejm. org/doi/full/10.1056/NEJMoa1407426).
  27. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014;371(17):1588–98 (https://pubmed.ncbi.nlm.nih. gov/25337748/).
  28. Jindani A, Harrison TS, Nunn AJ, Phillips PPJ, Churchyard GJ, Charalambous S et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014;371(17):1599–608 (https://www.nejm. org/doi/full/10.1056/NEJMoa1314210).
  29. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med. 2021;384(18):1705–18 (https://pubmed.ncbi.
  30. WHO operational handbook on tuberculosis Module 5: Management of tuberculosis in children and adolescents. Geneva: World Health Organization; 2022 ( retrieve).
  31. Turkova A, Wills GH, Wobudeya E, Chabala C, Palmer M, Kinikar A et al. Shorter treatment for nonsevere tuberculosis in African and Indian children. N Engl J Med. 2022;386(10):911–22 (https://pubmed.ncbi.nlm.
  32. WHO consolidated guidelines on tuberculosis Module 1: Prevention – tuberculosis preventive treatment. Geneva: World Health Organization; 2020 (
  33. Guideline: updates on the management of severe acute malnutrition in infants and children. Geneva: World Health Organization; 2013 ( pdf?sequence=1&isAllowed=y).
  34. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva: World Health Organization; 2007 (https://apps.who. int/iris/bitstream/handle/10665/43699/9789241595629_eng.pdf?sequence=1&isAllowed=y).
  35. Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD et al. Treatment of active tuberculosis in HIVcoinfected patients: a systematic review and meta-analysis. Clin Infect Dis. 2010;50(9):1288–99 (https://
  36. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva: World Health Organization; 2017 (
  37. WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders (WHO guidelines approved by the Guidelines Review Committee). Geneva: World Health Organization; 2012 (
  38. Meintjes G, Stek C, Blumenthal L, Thienemann F, Schutz C, Buyze J et al. Prednisone for the prevention of paradoxical tuberculosis-associated IRIS. N Engl J Med. 2018;379(20):1915–25 (https://pubmed.ncbi.nlm.
  39. Holden IK, Lillebaek T, Andersen PH, Bjerrum S, Wejse C, Johansen IS. Extrapulmonary tuberculosis in Denmark from 2009 to 2014; characteristics and predictors for treatment outcome. Open Forum Infect Dis. 2019;6(10):ofz388 (
  40. Bruchfeld J, Forsman LD, Fröberg G, Niward K. Extrapulmonary tuberculosis. In: Migliori GB & Raviglione MC (eds.), Essential tuberculosis. Switzerland: Springer, Cham; 2021:259–66 (https://doi. org/10.1007/978-3-030-66703-0_29).
  41. Fontanilla J-M, Barnes A, von Reyn CF. Current diagnosis and management of peripheral tuberculous lymphadenitis. Clin Infect Dis. 2011;53(6):555–62 (
  42. Rieder HL. Epidemiological basis of tuberculosis control. Paris: International Union Against Tuberculosis and Lung Disease; 1999 (
  43. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147–e95 (https://pubmed.
  44. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control (National Institute for Health and Clinical Excellence: Guidance). London: National Collaborating Centre for Chronic Conditions; 2006 (
  45. Treatment of tuberculosis. Morbidity and Mortality Weekly Report, American Thoracic Society, CDC and Infectious Diseases Society of America; 2003 ( htm).
  46. Treatment of tuberculosis: guidelines for national programmes, 4th edition. Geneva: World Health Organization; 2010 (
  47. Chotmongkol V, Jitpimolmard S, Thavornpitak Y. Corticosteroid in tuberculous meningitis. J Med Assoc Thai. 1996;79(2):83–90 (
  48. Kumarvelu S, Prasad K, Khosla A, Behari M, Ahuja GK. Randomized controlled trial of dexamethasone in tuberculous meningitis. Int J Tuberc Lung Dis. 1994;75(3):203–7 ( article/abs/pii/0962847994900094)
  49. Malhotra HS, Garg RK, Singh MK, Agarwal A, Verma R. Corticosteroids (dexamethasone versus intravenous methylprednisolone) in patients with tuberculous meningitis. Ann Trop Med Parasitol. 2009;103(7):625–34 (
  50. Schoeman JF, Van Zyl LE, Laubscher JA, Donald PR. Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis. Pediatrics. 1997;99(2):226–31 (
  51. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TTO, Nguyen TCT et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351(17):1741–51 (https://
  52. Mayosi BM, Ntsekhe M, Volmink JA, Commerford PJ. Interventions for treating tuberculous pericarditis. Cochrane Database Syst Rev. 2002;(4):CD000526 (
  53. Critchley JA, Young F, Orton L, Garner P. Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(3):223–37 (https://pubmed.ncbi.nlm.nih. gov/23369413/).
  54. Mayosi BM, Ntsekhe M, Bosch J, Pandie S, Jung H, Gumedze F et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med. 2014;371(12):1121–30 ( pdf/10.1056/NEJMoa1407380).
  55. Hakim JG, Ternouth I, Mushangi E, Siziya S, Robertson V, Malin A. Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients. Heart. 2000;84(2):183–8 (
  56. Reuter H, Burgess LJ, Louw VJ, Doubell AF. Experience with adjunctive corticosteroids in managing tuberculous pericarditis. Cardiovasc J S Afr. 2006;17(5):233–8 (
  57. Schrire V. Experience with pericarditis at Groote Schuur Hospital, Cape Town: an analysis of one hundred and sixty cases studied over a six-year period. S Afr Med J. 1959;33:810–7 (https://pubmed.ncbi.nlm.nih. gov/14443596/).
  58. Strang JI, Kakaza HH, Gibson DG, Allen BW, Mitchison DA, Evans DJ et al. Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet. 1988;2(8614):759–64 (
  59. Strang JI, Kakaza HH, Gibson DG, Girling DJ, Nunn AJ, Fox W. Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet. 1987;2(8573):1418–22 (https://
  60. GBD Tuberculosis Collaborators. The global burden of tuberculosis: results from the Global Burden of Disease Study 2015. Lancet Infect Dis. 2018;18(3):261–84 (
  61. Magis-Escurra C, Carvalho ACC, Kritski AL, Girardi E. Comorbidities. In: Migliori G, Bothamley G, Duarte R & Rendon A (eds.), Tuberculosis (ERS Monograph). Sheffield: European Respiratory Society; 2018:276–90 (
  62. Tiberi S, Pontali E, Tadolini M, D’Ambrosio L, Migliori GB. Challenging MDR-TB clinical problems - The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs. Int J Infect Dis. 2019;80S:S68–S72 (
  63. Zenner D, Kruijshaar ME, Andrews N, Abubakar I. Risk of tuberculosis in pregnancy: a national, primary care-based cohort and self-controlled case series study. Am J Respir Crit Care. 2012;185(7):779–84 (https://
  64. Nguenha D, Acacio S, Murias-Closas A, Ramanlal N, Saavedra B, Karajeanes E et al. Prevalence and clinical characteristics of pulmonary tuberculosis among pregnant and post-partum women in Mozambique. 2022.
  65. Jana N, Barik S, Arora N, Singh AK. Tuberculosis in pregnancy: the challenges for South Asian countries. J Obstet Gynaecol Res. 2012;38(9):1125–36 (
  66. LaCourse SM, Greene SA, Dawson-Hahn EE, Hawes SE. Risk of adverse infant outcomes associated with maternal tuberculosis in a low burden setting: a population-based retrospective cohort study. Infect Dis Obstet Gynecol. 2016;2016:6413713 (
  67. Chang C-W, Wu PW, Yeh C-H, Wong K-S, Wang C-J, Chang C-C. Congenital tuberculosis: case report and review of the literature. Paediatr Int Child Health. 2018;38(3):216–9 (https://pubmed.ncbi.nlm.nih. gov/28421876/).
  68. Sulis G, Gnanou S, Roggi A, Konseimbo A, Giorgetti PF, Castelli F et al. Active tuberculosis case finding among pregnant women: a pilot project in Burkina Faso. Int J Tuberc Lung Dis. 2016;20(10):1306–8 (https://
  69. Caminero JA, Scardigli A, van der Werf T, Tadolini M. Treatment of drug-susceptible and drug-resistant tuberculosis. In: Migliori G, Bothamley G, Duarte R & Rendon A (eds.), Tuberculosis (ERS Monograph). Sheffield: European Respiratory Society; 2018:152–78 ( treatment-of-drug-susceptible-and-drug-resistant-tuberculosis).
  70. Caminero JA, Lasserra P, Piubello A. Adverse anti-tuberculosis drug events and their management. In: Migliori G, Bothamley G, Duarte R & Rendon A (eds.), Tuberculosis (ERS Monograph). Sheffield: European Respiratory Society; 2018:205–27 (
  71. Schaaf HS, Marais BJ, Carvalho I. Challenges in childhood tuberculosis. In: Migliori G, Bothamley G, Duarte R & Rendon A (eds.), Tuberculosis (ERS Monograph). Sheffield: European Respiratory Society; 2018:234– 62 (
  72. Repossi A, Bothamley G. Tuberculosis in pregnancy and the elderly. In: Migliori G, Bothamley G, Duarte R & Rendon A (eds.), Tuberculosis (ERS Monograph). Sheffield: European Respiratory Society; 2018:263–75 (
  73. Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019;200(10):e93–e142 (
  74. Kawatsu L, Yoshiyama T, Kato S. Tuberculosis in the elderly. In: Migliori GB & Raviglione MC (eds.), Essential Tuberculosis. Cham, Switzerland: Springer; 2021:253–8 (
  75. Stead WW, Lofgren JP, Warren E, Thomas C. Tuberculosis as an endemic and nosocomial infection among the elderly in nursing homes. N Engl J Med. 1985;312(23):1483–7 (
  76. Prevention and control of tuberculosis in facilities providing long-term care to the elderly. Recommendations of the Advisory Committee for Elimination of Tuberculosis. Morbidity and Mortality Weekly Report, US: Centers for Disease Control and Prevention; 1990.
  77. Global burden of disease [website]. Institute for Health Metrics Evaluation; 2019 (https://www.healthdata. org/gbd/2019).
  78. Department of Epidemiology and Clinical Research [website]. Tokyo: The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association; 2022 (
  79. Lin H-S, Cheng C-W, Lin M-S, Chou Y-L, Chang P-J, Lin J-C et al. The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide. Clin Interv Aging. 2016;11:299–306 (
  80. Yoshiyama T. Tuberculosis treatment for patients more than 80 years old. Kekkaku: [Tuberculosis]. 2017;92(7):485–91 ( patients_more_than_eighty_years_old)
  81. Igari H, Imasawa T, Noguchi N, Nagayoshi M, Mizuno S, Ishikawa S et al. Advanced stage of chronic kidney disease is risk of poor treatment outcome for smear-positive pulmonary tuberculosis. J Infect Chemother. 2015;21(8):559–63 (
  82. Launay-Vacher V, Izzedine H, Deray G. Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure. Clin Pharmacokinet. 2005;44(3):221–35 (https://pubmed.ncbi.nlm.nih. gov/15762766/).
  83. Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet. 2007;370(9582):173–84 (https://pubmed.ncbi.
  84. Matsumoto K, Komukai J, Kasai S, Hirota S, Koda S, Terakawa K et al. [Evaluation of risk factors for failed/ defaulted on treatment outcomes of pulmonary tuberculosis in Osaka City]. Kekkaku: [Tuberculosis]. 2014;89(6):593–9 (
  85. Palmero D, Mendoza A. Clinical and programmatic aspects of kidney and liver failure and its impact on tuberculosis. In: Migliori GB & Raviglione MC (eds.), Essential Tuberculosis. Cham, Switzerland: Springer; 2021:267–74 (
  86. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis (WHO/HTM/TB/2014.11). Geneva: World Health Organization; 2015 ( iris/bitstream/handle/10665/130918/9789241548809_eng.pdf).
  87. Sonika U, Kar P. Tuberculosis and liver disease: management issues. Trop Gastroenterol. 2012;33(2):102–6 ( 
  88. Dhiman RK, Saraswat VA, Rajekar H, Reddy C, Chawla YK. A guide to the management of tuberculosis in patients with chronic liver disease. J Clin Exp Hepatol. 2012;2(3):260–70 (https://pubmed.ncbi.nlm.nih. gov/25755442/).
  89. Bosch A, Valour F, Dumitrescu O, Dumortier J, Radenne S, Pages-Ecochard M et al. A practical approach to tuberculosis diagnosis and treatment in liver transplant recipients in a low-prevalence area. Med Mal Infect. 2019;49(4):231–40 (
  90. Caminero JA, Migliori GB. Rationale for anti-tuberculosis chemotherapy. In: Migliori GB & Raviglione MC (eds.), Essential Tuberculosis. Cham, Switzerland: Springer; 2021:109–20 (https://doi. org/10.1007/978-3-030-66703-0_12).
  91. Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, Wejse C et al. MDR/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis. 2020;92S:S15–S25 (
  92. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020 (
  93. Mitnick CD, White RA, Lu C, Rodriguez CA, Bayona J, Becerra MC et al. Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. Eur Respir J. 2016;48(4):1160–70 (
  94. Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020;56(1):2000535 (
  95. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9(6):640–5 (
  96. Guidelines for the programmatic management of drug-resistant tuberculosis, 1st ed. (WHO/ HTM/TB/2006.361). Geneva: World Health Organization; 2006 ( eam/10665/246249/2/9789241546959-eng.pdf).
  97. Meeting report of the WHO expert consultation on drug-resistant tuberculosis treatment outcome definitions, 17–19 November 2020. Geneva: World Health Organization; 2021 ( handle/10665/340284).
  98. Linh NN, Viney K, Gegia M, Falzon D, Glaziou P, Floyd K et al. World Health Organization treatment outcome definitions for tuberculosis: 2021 update. Eur Respir J. 2021;58(2):2100804 (https://pubmed.ncbi.nlm.nih. gov/34413124/).
  99. Avaliani Z, Gozalov O, Kuchukhidze G, Skrahina A, Soltan V, van den Boom M et al. What is behind programmatic treatment outcome definitions for tuberculosis? Eur Clin Respir J. 2020;56(1):2001751 (https://
  100. Migliori GB, Marx FM, Ambrosino N, Zampogna E, Schaaf HS, van der Zalm MM et al. Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. Int J Tuberc Lung Dis. 2021;25(10):797–813 (

Book navigation